相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intravenously Administered Novel Liposomes, DCL64, Deliver Oligonucleotides to Cerebellar Purkinje Cells
Ana Tari Ashizawa et al.
CEREBELLUM (2019)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system
Julia F. Alterman et al.
NATURE BIOTECHNOLOGY (2019)
Suppression of Mutant Protein Expression in SCA3 and SCA1 Mice Using a CAG Repeat-Targeting Antisense Oligonucleotide
Eleni Kourkouta et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Genetics, Mechanisms, and Therapeutic Progress in Polyglutamine Spinocerebellar Ataxias
Ronald A. M. Buijsen et al.
NEUROTHERAPEUTICS (2019)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Therapeutic strategies for targeting neurodegenerative protein misfolding disorders
Robert H. Scannevin
CURRENT OPINION IN CHEMICAL BIOLOGY (2018)
Angubindin-1 opens the blood-brain barrier in vivo for delivery of antisense oligonucleotide to the central nervous system
Satoshi Zeniya et al.
JOURNAL OF CONTROLLED RELEASE (2018)
Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides
Shiyu Wang et al.
NUCLEIC ACIDS RESEARCH (2018)
A Sensitive In Vitro Approach to Assess the Hybridization-Dependent Toxic Potential of High Affinity Gapmer Oligonucleotides
Andreas Dieckmann et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Polyglutamine Repeats in Neurodegenerative Diseases
Andrew P. Lieberman et al.
Annual Review of Pathology-Mechanisms of Disease (2018)
Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7
Chenchen Niu et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease
Amber L. Southwell et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles
Jillian Friedrich et al.
JCI INSIGHT (2018)
Extracellular vesicles: Novel promising delivery systems for therapy of brain diseases
David Rufino-Ramos et al.
JOURNAL OF CONTROLLED RELEASE (2017)
RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus
Xue-Hai Liang et al.
MOLECULAR THERAPY (2017)
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Lindsay A. Becker et al.
NATURE (2017)
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Daniel R. Scoles et al.
NATURE (2017)
Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides
Naoki Iwamoto et al.
NATURE BIOTECHNOLOGY (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Polyglutamine spinocerebellar ataxias - from genes to potential treatments
Henry L. Paulson et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases
Kathleen M. Schoch et al.
NEURON (2017)
RNase H sequence preferences influence antisense oligonucleotide efficiency
Lukasz J. Kielpinski et al.
NUCLEIC ACIDS RESEARCH (2017)
Distribution and Penetration of Intracerebroventricularly Administered 2′OMePS Oligonucleotide in the Mouse Brain
Joao Casaca-Carreira et al.
NUCLEIC ACID THERAPEUTICS (2017)
Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
Lodewijk J. A. Toonen et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models
Lauren R. Moore et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
The expanded CAG repeat in the huntingtin gene as target for therapeutic RNA modulation throughout the HD mouse brain
Nicole A. Datson et al.
PLOS ONE (2017)
In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington's disease
Joao Casaca-Carreira et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels
Laura Rue et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Degenerative ataxias, from genes to therapies: The 2015 Cotzias Lecture
Stefan M. Pulst
NEUROLOGY (2016)
Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
Claudia A. Chiriboga et al.
NEUROLOGY (2016)
Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity
Xue-Hai Liang et al.
NUCLEIC ACIDS RESEARCH (2016)
Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver
Colton M. Miller et al.
NUCLEIC ACIDS RESEARCH (2016)
Splice-switching antisense oligonucleotides as therapeutic drugs
Mallory A. Havens et al.
NUCLEIC ACIDS RESEARCH (2016)
The delivery of therapeutic oligonucleotides
Rudolph L. Juliano
NUCLEIC ACIDS RESEARCH (2016)
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
Suzan M. Hammond et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Antisense oligonucleotide-mediated exon skipping as a strategy to reduce proteolytic cleavage of ataxin-3
Lodewijk J. A. Toonen et al.
SCIENTIFIC REPORTS (2016)
Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides
Takeshi Kasuya et al.
Scientific Reports (2016)
Cellular uptake and intracellular trafficking of oligonucleotides
R. L. Juliano et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy
Kentaro Sahashi et al.
HUMAN MOLECULAR GENETICS (2015)
Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression
Asad Jan et al.
NEUROSCIENCE LETTERS (2015)
Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2015)
The rates of the major steps in the molecular mechanism of RNase H1-dependent antisense oligonucleotide induced degradation of RNA
Timothy A. Vickers et al.
NUCLEIC ACIDS RESEARCH (2015)
Ataxin-2 Regulates RGS8 Translation in a New BAC-SCA2 Transgenic Mouse Model
Warunee Dansithong et al.
PLOS GENETICS (2015)
Huntington disease
Gillian P. Bates et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Calpain inhibition reduces ataxin-3 cleavage alleviating neuropathology and motor impairments in mouse models of Machado-Joseph disease
Ana Teresa Simoes et al.
HUMAN MOLECULAR GENETICS (2014)
Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity
Xin Sun et al.
HUMAN MOLECULAR GENETICS (2014)
Broad Therapeutic Benefit After RNAi Expression Vector Delivery to Deep Cerebellar Nuclei: Implications for Spinocerebellar Ataxia Type 1 Therapy
Megan S. Keiser et al.
MOLECULAR THERAPY (2014)
In Vivo Evaluation of Candidate Allele-specific Mutant Huntingtin Gene Silencing Antisense Oligonucleotides
Amber L. Southwell et al.
MOLECULAR THERAPY (2014)
Systemic Exosomal siRNA Delivery Reduced Alpha-Synuclein Aggregates in Brains of Transgenic Mice
J. Mark Cooper et al.
MOVEMENT DISORDERS (2014)
Nonsense-mediated decay as a terminating mechanism for antisense oligonucleotides
Amanda J. Ward et al.
NUCLEIC ACIDS RESEARCH (2014)
TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells
Xue-hai Liang et al.
NUCLEIC ACIDS RESEARCH (2014)
Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients
Niels H. Skotte et al.
PLOS ONE (2014)
Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification
Melvin M. Evers et al.
NUCLEIC ACID THERAPEUTICS (2014)
Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy
Andrew P. Lieberman et al.
CELL REPORTS (2014)
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl-Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates
Frank Rigo et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Changes in Purkinje cell firing and gene expression precede behavioral pathology in a mouse model of SCA2
Stephen T. Hansen et al.
HUMAN MOLECULAR GENETICS (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study (vol 12, pg 435, 2013)
T. M. Miller et al.
LANCET NEUROLOGY (2013)
Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon
Melvin M. Evers et al.
NEUROBIOLOGY OF DISEASE (2013)
Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA
Sarah L. DeVos et al.
NEUROTHERAPEUTICS (2013)
Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2013)
Soluble forms of polyQ-expanded huntingtin rather than large aggregates cause endoplasmic reticulum stress
Julia Leitman et al.
NATURE COMMUNICATIONS (2013)
Translation of HTT mRNA with expanded CAG repeats is regulated by the MID1-PP2A protein complex
Sybille Krauss et al.
NATURE COMMUNICATIONS (2013)
Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
JOURNAL OF HUNTINGTONS DISEASE (2013)
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Timothy M. Miller et al.
LANCET NEUROLOGY (2013)
Cell biology of spinocerebellar ataxia
Harry T. Orr
JOURNAL OF CELL BIOLOGY (2012)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Targeting a pre-mRNA structure with bipartite antisense molecules modulates tau alternative splicing
Eleanor Peacey et al.
NUCLEIC ACIDS RESEARCH (2012)
MicroRNAs in neurodegenerative diseases and their therapeutic potential
Eunsung Junn et al.
PHARMACOLOGY & THERAPEUTICS (2012)
Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases
Amber L. Southwell et al.
TRENDS IN MOLECULAR MEDICINE (2012)
A Pathogenic Mechanism in Huntington's Disease Involves Small CAG-Repeated RNAs with Neurotoxic Activity
Monica Banez-Coronel et al.
PLOS GENETICS (2012)
Impaired motoneuronal retrograde transport in two models of SBMA implicates two sites of androgen action
Michael Q. Kemp et al.
HUMAN MOLECULAR GENETICS (2011)
Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum
Liutao Du et al.
HUMAN MOLECULAR GENETICS (2011)
Early Changes in Cerebellar Physiology Accompany Motor Dysfunction in the Polyglutamine Disease Spinocerebellar Ataxia Type 3
Vikram G. Shakkottai et al.
JOURNAL OF NEUROSCIENCE (2011)
Huntington's disease: from molecular pathogenesis to clinical treatment
Christopher A. Ross et al.
LANCET NEUROLOGY (2011)
Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene/Allele-Specific Silencing of Mutant Huntingtin
Jeffrey B. Carroll et al.
MOLECULAR THERAPY (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Lydia Alvarez-Erviti et al.
NATURE BIOTECHNOLOGY (2011)
CAG repeats mimic CUG repeats in the misregulation of alternative splicing
Agnieszka Mykowska et al.
NUCLEIC ACIDS RESEARCH (2011)
Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes
Erich Koller et al.
NUCLEIC ACIDS RESEARCH (2011)
Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide
Melvin M. Evers et al.
PLOS ONE (2011)
Polyglutamine diseases: The special case of ataxin-3 and Machado-Joseph disease
Carlos A. Matos et al.
PROGRESS IN NEUROBIOLOGY (2011)
Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
Marco A. Passini et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Yimin Hua et al.
GENES & DEVELOPMENT (2010)
Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
Sandro Alves et al.
HUMAN MOLECULAR GENETICS (2010)
Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis
Kristina Becanovic et al.
HUMAN MOLECULAR GENETICS (2010)
Alternating 2′-O-ribose methylation is a universal approach for generating non-stimulatory siRNA by acting as TLR7 antagonist
Svetlana Hamm et al.
IMMUNOBIOLOGY (2010)
Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease
Christian Landles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS
Andrew C. Elden et al.
NATURE (2010)
Repeat expansion disease: progress and puzzles in disease pathogenesis
Albert R. La Spada et al.
NATURE REVIEWS GENETICS (2010)
Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor
Xin Ming et al.
NUCLEIC ACIDS RESEARCH (2010)
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Chiara Zuccato et al.
PHYSIOLOGICAL REVIEWS (2010)
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN
Richard S. Geary et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin
Mahmoud A. Pouladi et al.
BRAIN (2009)
Ribonuclease H: the enzymes in eukaryotes
Susana M. Cerritelli et al.
FEBS JOURNAL (2009)
Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses
Sibylle Tluk et al.
INTERNATIONAL IMMUNOLOGY (2009)
Pathogenic Mechanisms of a Polyglutamine-mediated Neurodegenerative Disease, Spinocerebellar Ataxia Type 1
Huda Y. Zoghbi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells
Tamara Ratovitski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Short Antisense Oligonucleotides with Novel 2′-4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Punit P. Seth et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs
Jiaxin Hu et al.
NATURE BIOTECHNOLOGY (2009)
Dissociated Fear and Spatial Learning in Mice with Deficiency of Ataxin-2
Duong P. Huynh et al.
PLOS ONE (2009)
Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in Transgenic mice
Yimin Hua et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2008)
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice
Natee Jearawiriyapaisarn et al.
MOLECULAR THERAPY (2008)
New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
Rintaro Hashizume et al.
NEURO-ONCOLOGY (2008)
Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis
Md Rowshon Alam et al.
NUCLEIC ACIDS RESEARCH (2008)
Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic
Toshiaki Takahashi et al.
HUMAN MOLECULAR GENETICS (2008)
Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate
Walt F. Lima et al.
MOLECULAR PHARMACOLOGY (2007)
Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals
Eric E. Swayze et al.
NUCLEIC ACIDS RESEARCH (2007)
Reversible disruption of dynactin 1-mediated retrograde axonal transport in polyglutamine-induced motor neuron degeneration
Masahisa Katsuno et al.
JOURNAL OF NEUROSCIENCE (2006)
Antisense oligonucleotide therapy for neurodegenerative disease
Richard A. Smith et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin
Rona K. Graham et al.
CELL (2006)
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
J Alter et al.
NATURE MEDICINE (2006)
Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302)
Tanya A. Watanabe et al.
OLIGONUCLEOTIDES (2006)
Spinal distribution and metabolism of 2 '-O-(2-methoxyethyl)-modified oligonucleotides after intrathecal administration in rats
M Butler et al.
NEUROSCIENCE (2005)
Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs
HJ Wu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia
HB Xia et al.
NATURE MEDICINE (2004)
Antisense technologies - Improvement through novel chemical modifications
J Kurreck
EUROPEAN JOURNAL OF BIOCHEMISTRY (2003)
Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
I Sánchez et al.
NATURE (2003)
Nuclease stability of LNA oligonucleotides and LNA-DNA chimeras
M Frieden et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2003)
Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design
DA Braasch et al.
NUCLEIC ACIDS RESEARCH (2002)
Trafficking of intracerebroventricularly injected antisense oligonucleotides in the mouse brain
NB Chauhan
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor
AP Lieberman et al.
HUMAN MOLECULAR GENETICS (2002)
Proteases acting on mutant Huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions
A Lunkes et al.
MOLECULAR CELL (2002)
Fully modified 2′ MOE oligonucleotides redirect polyadenylation
TA Vickers et al.
NUCLEIC ACIDS RESEARCH (2001)
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice
I Dragatsis et al.
NATURE GENETICS (2000)
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
C Wahlestedt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
